Skip to main content

Closed

SRPT: Sarepta Therapeutics, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+53.0% / yr

Operating margin-1.9%

ROIC-1.5%

Financially safe

Stretched

Debt / equity0.69×

Interest coverage-1.0×

Current ratio4.63×

Valuation

Unrated

P/E ratio24.0×

Sarepta Therapeutics, Inc.

SRPTNASDAQ Global Select·USD·Closed

Sarepta Therapeutics, Inc.

SRPTNASDAQ·USD·Closed

$14.86

−4.50%

$14.86

−$0.70 (4.50%)

52W Range

2thpctl

Volume

1.06×avg

Mkt Cap

1.57BUSD

P/E

24.0TTM

Div Yield

–ann

52W Range

2thpctl

Volume

1.06×avg

Market Cap

1.57BUSD

P/E Ratio

24.0TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings